<DOC>
	<DOC>NCT00010400</DOC>
	<brief_summary>OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II. Determine the toxicity of this drug in these patients.</brief_summary>
	<brief_title>Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover. Patients are followed monthly for 6 months, and then every 3 months thereafter.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Antiphospholipid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Diagnosis of lifethreatening systemic lupus erythematosus (SLE); must show at least 4 American College of Rheumatology criteria for SLE; must have severe organ damage in 1 or more organs; must have 1 or more of the following indications of ongoing disease activity: disease activity score (SLEDAI) at least 4, hospitalization for disease activity within 12 months, lifethreatening disease not captured on SLEDAI OR Diagnosis of antiphospholipid antibody syndrome by the Hughes criteria; must show severity by ongoing symptoms or signs of hypercoagulability in spite of warfarin therapy Patient Characteristics Hepatic: Bilirubin no greater than 2.0 mg/dL; transaminases no greater than 2.0 times normal Renal: Creatinine no greater than 3.0 mg/dL Cardiovascular: Ejection fraction at least 45% Pulmonary: FVC, FEV1, or DLCO at least 50% predicted Other: Not preterminal or moribund; not pregnant or nursing; fertile patients must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>antiphospholipid antibody syndrome</keyword>
	<keyword>arthritis &amp; connective tissue diseases</keyword>
	<keyword>immunologic disorders and infectious disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>